Results 191 to 200 of about 734,103 (389)
Specific Targets in Sarcoma and Developmental Therapeutics [PDF]
, 2010 David M. Thomas, Andrew J. Wagner
openalex +1 more source
Metabolism‐Regulating Nanomedicines for Cancer Therapy
Advanced NanoBiomed Research, EarlyView.This review highlights metabolism‐regulating nanomedicines designed to target glycolytic, lipid, amino acid, and nucleotide pathways in tumors. By incorporating metabolism‐regulating agents into versatile nanocarriers such as liposomes, micelles, dendrimers, and engineered bacteria, these platforms achieve targeted delivery, controlled release ...
Xiao Wu, Shiyi Geng, Jian Yang
wiley +1 more source
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.
Blood, 1995 J. Soulier +10 more
semanticscholar +1 more source
3D Hydrogel Cell Cultures and Their Biomedical Applications
Advanced NanoBiomed Research, EarlyView.The review highlights the advantages of hydrogel‐based 3D cell cultures over traditional 2D models. These hydrogels closely mimic natural cellular environments, improving research in tissue engineering, drug discovery, cancer studies, and neuroscience.
Tri Lan Thai +7 more
wiley +1 more source
What's in a name? Molecular subclassification of sarcomas creates fresh challenges [PDF]
, 2018 Juan Dı́az-Martı́n +5 more
openalex +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Cytological Diagnosis of Metastatic Sarcomas in Body Fluids and Correlation With Immunohistochemical/Molecular Studies: A Retrospective Study of Cytologic Cases [PDF]
, 2015 Sarah Karram, Susan Geddes, Qing Kay Li
openalex +1 more source